IBRX
ImmunityBio·NASDAQ
--
--(--)
--
--(--)
6.02 / 10
Outperform
Money flow analysis registers 7.75/10, showing robust fund flow characteristics. Positive momentum in Small, Medium, and Extra-large is countered by negative tendencies in overall, block, and Large, suggesting positive flow conditions. Analyst consensus points to overwhelmingly bullish analyst consensus with strong conviction. Distribution analysis: Strong Buy(85.7%), Buy(14.3%) among 7 research opinions, supported by 4.29 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
86%
Buy
14%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-26
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for IBRX?
- IBRX holds a Bearish analyst rating, with 86% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.02/10 (Outperform).
